BRIEF published on 12/17/2025 at 14:43, 8 months 21 days ago First Berlin Equity Research met à jour sa recommandation sur Cardiol Therapeutics, passant à « Acheter » avec un objectif de cours abaissé. Recommandation D'achat Ajustement Du Prix Cible Thérapeutique Cardiaque Étude ARCHER De Phase II Myocardite
PRESS RELEASE published on 12/17/2025 at 14:38, 8 months 21 days ago Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc., lowering price target to USD 7.80 based on positive Phase II ARCHER data on CardiolRx for acute myocarditis First Berlin Equity Research Buy Recommendation Acute Myocarditis Cardiol Therapeutics Inc. Phase II ARCHER Data
BRIEF published on 10/23/2025 at 12:56, 10 months 15 days ago Cardiol Therapeutics obtient un financement avec un placement privé de 11,4 millions de dollars Placement Privé Essais Cliniques Cardiol Therapeutics Perspectives Financières Traitement De L'insuffisance Cardiaque
BRIEF published on 10/23/2025 at 12:56, 10 months 15 days ago Cardiol Therapeutics Secures Funding with USD 11.4 Million Private Placement Private Placement Clinical Trials Financial Outlook Cardiol Therapeutics Heart-Failure Therapy
PRESS RELEASE published on 10/23/2025 at 12:51, 10 months 15 days ago Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research updates Cardiol Therapeutics Inc with a BUY rating and USD 8.50 price target. The private placement secures funds for pivotal trials and new product development Private Placement Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating USD 8.50 Price Target
BRIEF published on 08/12/2025 at 13:36, 1 year ago Cardiol Therapeutics: Phase II Trial Results and Positive Stock Outlook BUY Rating Cardiol Therapeutics CardiolRx Phase II ARCHER Trial Acute Myocarditis
BRIEF published on 08/12/2025 at 13:36, 1 year ago Cardiol Therapeutics : résultats de l'essai de phase II et perspectives boursières positives Cardiol Therapeutics Acheter Une Note CardiolRx Essai ARCHER De Phase II Myocardite Aiguë
PRESS RELEASE published on 08/12/2025 at 13:31, 1 year ago Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc after positive phase II trial results for CardiolRx in acute myocarditis Cardiol Therapeutics Inc First Berlin Equity Research Phase II Trial CardiolRx Acute Myocarditis
BRIEF published on 04/23/2025 at 15:29, 1 year 4 months ago Cardiol Therapeutics Advances in Pivotal Phase III Study FDA Approval Cardiol Therapeutics Phase III Study Recurrent Pericarditis CardiolRxT
BRIEF published on 04/23/2025 at 15:29, 1 year 4 months ago Cardiol Therapeutics progresse dans l'étude pivot de phase III Cardiol Therapeutics Approbation De La FDA Étude De Phase III Péricardite Récurrente CardiolRxT
Published on 09/05/2026 at 04:05, 2 days 12 hours ago Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 2 days 16 hours ago FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 2 days 17 hours ago Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 2 days 17 hours ago Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/04/2026 at 14:30, 3 days 1 hour ago Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Published on 09/07/2026 at 08:30, 7 hours 35 minutes ago Dépôt d’une actualisation du document d’enregistrement universel
Published on 09/07/2026 at 08:25, 7 hours 39 minutes ago Dépôt d’une actualisation du document d’enregistrement universel
Published on 09/07/2026 at 08:20, 7 hours 44 minutes ago Derichebourg annonce le lancement d’une offre d’obligations vertes senior
